Document:

EX-10.2.3

 Exhibit 10.2.3 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
 AMENDMENT NO. 3 TO THE PATENT LICENSE AGREEMENT NO. C-00061906 

BETWEEN: 
 L’Institut Pasteur, a public
interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Jean Castex, adjunct General Manager for administration and finance, 

Hereafter referred to as “IP” or the “Licensor”, 

Party of the first part, 
 AND: 

CELLECTIS, CELLECTIS 
 Public limited company with capital
with a capital of 122,363.47 euros, 
 with its registered office at 102, route de Noisy, 93235 Romainville cedex, 

represented by Mr. André Choulika, acting in the capacity of CEO 

Hereafter referred to as “CELLECTIS” or the “LICENSEE”, 

Party of the second part. 
 The LICENSOR and LICENSEE are
hereafter referred to as the “Parties”. 
 RECITALS: 

IP owns patents and patent applications relating to a method of homologous recombination. 

On June 19, 2000, the Parties signed license agreement no. C-00061906 (hereafter the “AGREEMENT”), by which the LICENSOR grants the LICENSEE
exploitation rights to the above mentioned patents and patent applications. 
 The AGREEMENT was the subject of a first amendment signed on
September 8, 2003 and a second amendment dated June 24, 2004 modifying the FIELD of the AGREEMENT. 
 After discussions and exchanges between the
Parties, they have decided to modify the provisions of the AGREEMENT. 
 It is thus agreed as follows: 

ARTICLE 1 
  

	1.1	The Parties agree that the words defined in Article 1, “DEFINITIONS”, of the AGREEMENT, as they are used in this amendment, have the same definitions as in the AGREEMENT and form an integral part of this
amendment. 

 ARTICLE 2 

Article 1.3 of the AGREEMENT is modified by the following provisions, which supersede all previous provisions of the same article: 

1.2 FIELD 
 FIELD of the
AGREEMENT covers the field of homologous recombination applied to all genes other than those that code for Erythropoietin (EPO). 
 ARTICLE 3

 Article 2.1 of the AGREEMENT is modified by the following provisions, which supersede all previous provisions of the same article: 

2.1 The LICENSOR grants, under the terms and conditions specified herein, to the LICENSEE, who accepts this, an exclusive license for the
AGREEMENT PATENTS under the AGREEMENT to make, have made, use and sell the LICENSED PRODUCTS and/or implement or have implemented the LICENSED PROCESSES in the TERRITORY within the FIELD during the term of this AGREEMENT. 

ARTICLE 4 
 Under this Amendment, the LICENSEE will
pay the LICENSOR, 60 days from the date of signature of this Amendment, a fixed, non-refundable and non-deductible payment of [***]. 
 ARTICLE 5

 This Amendment will enter into force on the date of its signature. 

The AGREEMENT’s other provisions remain unchanged and in force between the Parties. 

Signed in Paris on            [Handwritten text: August 24, 2005] 

in 2 original copies. 
  

			
	CELLECTIS		INSTITUT PASTEUR

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY
FILED WITH THE COMMISSION.EX-10.2.4

 Exhibit 10.2.4 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
 SCHEDULE A 

AMENDMENT NO. 4 TO PATENT LICENSING AGREEMENT NO. C-00061906 

BETWEEN: 
 INSTITUT PASTEUR, a public interest
foundation, headquartered at 25, rue du Docteur Roux, 75015 Paris, 
 Hereafter referred to as the “LICENSOR” 

Party of the first part 
 AND: 

CELLECTIS, a public limited company, headquartered at 102, route de Noisy, 93235 Romainville Cedex, 

Hereafter referred to as “CELLECTIS” or the “LICENSEE”, 

Party of the second part. 
 The LICENSOR
and LICENSEE are hereafter referred to as the “Parties”. 
 RECITALS: 

Institut Pasteur owns patents and patent applications concerning a homologous recombination method. 

On June 19, 2000, the Parties signed the license agreement no. C-00061906 (hereafter the “AGREEMENT”), by which the LICENSOR grants the
LICENSEE exploitation rights to the above mentioned patents and patent applications. 
 The AGREEMENT was the subject of a first amendment dated
September 9, 2003, a second amendment dated June 24, 2004 modifying the FIELD of the AGREEMENT and a third amendment dated August 24, 2005. 

After discussions and exchanges between the Parties, they have decided to modify the provisions of the AGREEMENT. 

It is thus agreed as follows: 
 ARTICLE 1

 The Parties agree that the words defined in article 1 - “DEFINITIONS” of the AGREEMENT which are not modified by this amendment shall
have the same definitions as in the AGREEMENT and form an integral part of this amendment. 

 ARTICLE 2 

Article 1 of the AGREEMENT is supplemented by the following provision: 
  

	1.2	FIELD 

 The FIELD of the AGREEMENT is extended to Erythropoietin (hereafter EPO). 

ARTICLE 3 
 As an exception to the provisions of
paragraph 1.2 as stated in article 2 above, the LICENSEE acknowledges that the LICENSOR has directly granted a license for the AGREEMENT PATENTS under the AGREEMENT to the company [***] in the sole domain of Erythropoietin. 

[***]. 
 ARTICLE 4 

In the three (3) months following the signing of this amendment, the LICENSEE will pay to the LICENSOR the amount of [***] as an advance for the royalties
that will be owed by the LICENSEE to the LICENSOR for the sublicenses relating to EPO. 
 ARTICLE 5 

Within the framework of the provisions of Article 7 of the Agreement, the LICENSEE shall pursue charges for the infringement of the AGREEMENT PATENTS under the
AGREEMENT against potential infringers. 
 In application of articles 7.1, 7.2 and 7.3, the LICENSOR agrees to cooperate with the LICENSEE in order to
define the legal, scientific or patent arguments that may be used to determine patent infringement and defend the validity or scope of the AGREEMENT PATENTS under the AGREEMENT. 

The LICENSEE will negotiate in order to grant sub-licenses, in accordance with Article 2.3 and, in the event of failure of the negotiations entered into, may
pursue patent infringers identified under paragraphs 7.3, 7.4, 7.5, 7.6 and 7.7 of the Agreement. The LICENSOR may participate in the proceedings or not, as it prefers, in accordance with these same provisions of the AGREEMENT. 

In accordance with the provisions of Article 7.7 of the AGREEMENT, the LICENSOR agrees to provide all documents, powers and signatures that may be required by
the LICENSEE to complete the actions taken. 
 ARTICLE 6 

The Parties have decided to create a joint monitoring committee made up of four members for the purpose of (i) monitoring mutual exchanges of information
concerning the implementation of Articles 2.2 and 2.4 of the AGREEMENT, which either of the Parties has identified, (ii) examine any IMPROVEMENT and/or KNOW-HOW that is identified by either of the Parties, and (iii) monitor patent
infringement cases as set forth in article 5 above. 
 Any IMPROVEMENT or KNOW-HOW will be subject to Articles 2.2 and 2.4 (modified by amendment no. 1) of
the AGREEMENT. 
  
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH
THE COMMISSION. 

 Within fifteen (15) days following the signing of this amendment, each of the Parties will inform the other
Party of the names of two committee representatives. 
 This committee must meet within the fifteen (15) days following its formation and define its
rules of procedure, which it will immediately notify to the Parties. 
 ARTICLE 7 

The LICENSOR grants the LICENSEE a modification to the royalty rate specified in Article 3.4 of the Agreement for the sub-licenses, with the following
conditions: 
  

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is lesser or equal to [***] 

 

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is between [***] 

 

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is between [***] 

 

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is greater than [***] 

ARTICLE 8 
 Within the framework of article 7 of
the AGREEMENT, in the event that the LICENSOR does not wish to pursue a patent infringer and that a favorable outcome has been found for the LICENSEE, either through a transaction, or through the award of a sub-license, or by a legal decision, the
Parties agree to grant the LICENSEE, as a bonus, a revision of the rates stipulated in Article 7 of this amendment, as follows: 
  

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is lesser or equal to [***] 

 

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is between [***] 

 

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is between [***] 

 

	•	 	[***] of all compensation received by the LICENSEE as discussed in Article 3.4 of the Agreement for the part of the amounts collected by the LICENSEE over the year which is greater than [***] 

 
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION.

 ARTICLE 9 

This amendment shall enter into force on the date of its signature. 

ARTICLE 10 
 The provisions of the AGREEMENT and
the amendments which are not modified by this amendment shall remain unchanged and in force between the Parties. 
 Signed in Paris on
            [Handwritten text: December 27, 2007] 
 In 2 original copies. 

 

			
	For CELLECTIS		For INSTITUT PASTEUR

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]